Callan Capital LLC Sells 174 Shares of Zoetis Inc. (NYSE:ZTS)

Callan Capital LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 5.8% in the 4th quarter, Holdings Channel.com reports. The fund owned 2,827 shares of the company’s stock after selling 174 shares during the quarter. Callan Capital LLC’s holdings in Zoetis were worth $461,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Atlantic Edge Private Wealth Management LLC increased its position in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 140 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in shares of Zoetis during the third quarter valued at approximately $31,000. First Personal Financial Services bought a new stake in shares of Zoetis during the third quarter valued at approximately $33,000. Capital Performance Advisors LLP bought a new stake in shares of Zoetis during the third quarter valued at approximately $33,000. Finally, Dunhill Financial LLC increased its position in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 1.9 %

Shares of Zoetis stock opened at $160.39 on Friday. The company’s fifty day simple moving average is $166.51 and its 200-day simple moving average is $177.99. The stock has a market capitalization of $71.82 billion, a PE ratio of 29.32, a P/E/G ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.25%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ZTS has been the subject of several analyst reports. Stifel Nicolaus reduced their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Barclays lifted their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Piper Sandler cut their target price on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Morgan Stanley cut their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Zoetis currently has an average rating of “Buy” and an average price target of $215.40.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.